Recent News

• 07.30.2026 - Castle Biosciences Reports Second Quarter 2026 Results
• 07.22.2026 - Castle Biosciences to Present at the Canaccord Genuity 46th Annual Growth Conference
• 07.14.2026 - Castle Biosciences Announces New York State Department of Health Approval of its AdvanceAD-Tx™ Test
• 07.09.2026 - Castle Biosciences to Release Second Quarter 2026 Financial Results and Host Webcast on Thursday, July 30, 2026
• 06.25.2026 - DecisionDx®-Melanoma's i31-SLNB Outperforms MIA Nomogram in Identifying Patients Who May Safely Forgo Sentinel Lymph Node Biopsy
• 06.23.2026 - Castle Biosciences' Chief Financial Officer Frank Stokes Named a 2026 CFO Awards Honoree by the Houston Business Journal
• 06.19.2026 - Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 06.16.2026 - Castle Biosciences' TissueCypher® Test Surpasses 100,000 Orders, Advancing Precision Risk Assessment for Patients with Barrett's Esophagus

Recent Filings

• 07.31.2026 - 144 Report of proposed sale of securities
• 07.31.2026 - 144 Report of proposed sale of securities
• 07.30.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 07.30.2026 - EX-99.1 EX-99.1
• 07.30.2026 - 8-K Current report
• 07.29.2026 - 4 Statement of changes in beneficial ownership of securities
• 07.16.2026 - 4 Statement of changes in beneficial ownership of securities
• 07.06.2026 - 4 Statement of changes in beneficial ownership of securities
• 07.06.2026 - 4 Statement of changes in beneficial ownership of securities
• 07.01.2026 - 144 Report of proposed sale of securities